Zepteon: Separation of Nonfucosylated Antibodies Zepteon, Inc. is a privately held corporation founded in 2012 that has developed a first in class chromatography resin, Glycap-3A, capable of separating antibodies with specific sugar structures (nonfucosylated) that are more potent against diseases like cancer. The Glycap-3A resin has been bought and used by more than half of the largest pharmaceutical companies. Zepteonís Glycap-3A chromatography resin can be used to make biosimilar antibodies with targeted nonfucose levels. The Zepteon technology can enable preparation of a robust biosimilar antibody filing, increasing the chances of regulatory success and increasing speed to market (Pace et. al, Biotech Prog, June 2016; btpr.2300). In addition, Zepteon is the lowest cost supplier of the protein receptor FcgammaRIIIa.